CN113350348B - Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity - Google Patents
Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity Download PDFInfo
- Publication number
- CN113350348B CN113350348B CN202110854248.4A CN202110854248A CN113350348B CN 113350348 B CN113350348 B CN 113350348B CN 202110854248 A CN202110854248 A CN 202110854248A CN 113350348 B CN113350348 B CN 113350348B
- Authority
- CN
- China
- Prior art keywords
- benzhydryl
- compound
- piperazine
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 210000005027 intestinal barrier Anatomy 0.000 title claims abstract description 13
- 230000007358 intestinal barrier function Effects 0.000 title claims abstract description 13
- -1 1-benzhydryl-4-methylpiperazine compound Chemical class 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- RVERZAZDFDPJPF-UHFFFAOYSA-N 1-benzhydryl-4-[(1-phenyltriazol-4-yl)methyl]piperazine Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)N1CCN(CC1)CC=1N=NN(C=1)C1=CC=CC=C1 RVERZAZDFDPJPF-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000000968 intestinal effect Effects 0.000 claims abstract description 22
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 9
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 9
- 102000003940 Occludin Human genes 0.000 claims description 10
- 108090000304 Occludin Proteins 0.000 claims description 10
- 102000004057 Claudin-5 Human genes 0.000 claims description 6
- 108090000582 Claudin-5 Proteins 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 5
- 241000588771 Morganella <proteobacterium> Species 0.000 claims description 4
- 241000605947 Roseburia Species 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 241000466670 Adlercreutzia Species 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 25
- 241000699670 Mus sp. Species 0.000 abstract description 20
- 230000001684 chronic effect Effects 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 230000035882 stress Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 229960002464 fluoxetine Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000566145 Otus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000160321 Parabacteroides Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a 1-benzhydryl-4-methylpiperazine compound in preparing a medicine for protecting the integrity of intestinal barriers, belonging to the field of medicines, wherein the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can obviously improve the behavior of depression of a chronic unpredictable stress model mouse. Mechanism research shows that the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can improve the disorder of intestinal flora of mice induced by a chronic unpredictable stress model; and has protective effect on intestinal barrier and blood brain barrier integrity.
Description
Technical Field
The disclosure belongs to the technical field of medicines, and particularly relates to application of a compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine in preparation of a medicine for protecting the integrity of intestinal barriers.
Background
The intestinal tract of human body inhabits a large amount of bacteria, the total number can reach 1013-1014And about 10 times of the number of human cells. The number of genes contained in the intestinal flora is about 100 times the number of the human body's own genome, and thus the human intestinal flora is considered to be an "organ" of the human body or a second genome of the human body. Studies have shown that the intestinal flora not only has a profound effect on the basal metabolism of the host organism.
Disclosure of Invention
Aiming at the defects of the prior art, the purpose of the disclosure is to provide the application of a compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine in the preparation of a medicine for protecting the integrity of intestinal barriers, and the purpose of treating depression by improving intestinal flora disorder is realized.
The purpose of the disclosure can be realized by the following technical scheme:
application of a compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine in preparation of anti-depression drugs.
Further, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used for improving intestinal flora disturbance: increase the overall richness and diversity of the intestinal flora.
Further, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used for reducing the relative abundance of Por _ parabacter, Bac _ bacteria and Ent _ Morganella in the intestinal tract and increasing the relative abundance of Cor _ adrecrreutzia, Lac _ Roseburia and Pas _ agregbacter.
Further, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used for protecting the integrity of intestinal barriers and increasing the expression of ZO-1 and Occludin proteins in intestinal tissues.
Further, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used for protecting the integrity of a blood brain barrier and increasing the expression of ZO-1, Occludin and Claudin-5 proteins in brain tissues.
Furthermore, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is applied to anti-depression drugs or health care products.
Furthermore, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is applied to medicines or health care products for improving intestinal flora disorder.
Furthermore, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is applied to medicines or health care products for protecting the integrity of intestinal barriers.
Furthermore, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is applied to medicines or health care products for protecting the integrity of a blood brain barrier.
The beneficial effect of this disclosure:
can improve intestinal barrier integrity symptoms by improving intestinal flora disorder.
Drawings
In order to more clearly illustrate the embodiments or technical solutions in the prior art of the present disclosure, the drawings used in the description of the embodiments or prior art will be briefly described below, and it is obvious for those skilled in the art that other drawings can be obtained based on these drawings without creative efforts.
FIG. 1 shows that 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine, a compound, has an improvement effect on depression-like behaviors of mice induced by a chronic unpredictable stress model;
FIG. 2 shows the improvement effect of 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine on the reduction of the integral abundance and diversity of mouse intestinal flora induced by a chronic unpredictable stress model;
FIG. 3 shows the improvement effect of 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine on the relative abundance change of mouse intestinal flora level induced by a chronic unpredictable stress model;
FIG. 4 shows that 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine, a compound, has an improvement effect on the relative abundance of significantly changed genera in mouse intestinal flora induced by a chronic unpredictable stress model;
FIG. 5 shows the improvement effect of 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine on the barrier integrity injury of the intestinal tract of a mouse induced by a chronic unpredictable stress model;
FIG. 6 shows that 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine, a compound, has an improvement effect on blood brain barrier integrity damage of mice induced by a chronic unpredictable stress model.
Detailed Description
The technical solutions in the embodiments of the present disclosure will be clearly and completely described below with reference to the drawings in the embodiments of the present disclosure, and it is obvious that the described embodiments are only a part of the embodiments of the present disclosure, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments disclosed herein without making any creative effort, shall fall within the protection scope of the present disclosure.
Example 1 establishment of chronic unpredictable stress model in mice:
mice were modeled as chronic unpredictable stress by exposing them to various randomly arranged low social and environmental stress sources 1-2 times a day for 4 weeks.
The random pressure source comprises: 1) binding for 6 hours; 2) the 45-degree squirrel cage is inclined for 3 hours along a vertical axis; 3) fasting with water (for 24 hours, then return to normal); 4) the day and night illumination is reversed; 5) raising for 24 hours without padding; 6) tail pinching for 1 minute (1 cm from the root of the tail); 7) padding for 24 hours in a wet mode; 8) forced swimming for 5 minutes at 8 ℃.
Grouping experiments:
1) control group: a control mouse;
2) model group: molding by adopting the chronic unpredictable stress model;
3) positive reference group: adopting fluoxetine as a positive reference drug, and carrying out intraperitoneal injection administration for 4 weeks at a dose of 10 mg/kg/day;
4) group of compounds: the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is adopted for treatment, and is administrated by intraperitoneal injection, wherein the dosage is 10 mg/kg/day and the duration is 4 weeks.
Example 2 sucrose preference test
The sucrose preference test is performed in three stages: first stage habituation, second stage sucrose preference baseline, and third stage sucrose preference test. The first stage is as follows: rats were acclimatized with 1% sucrose. And a second stage: each mouse was housed in a single cage, and the mice were given equal amounts of plain drinking water and 1% sucrose solution, and the positions of the plain drinking water and sucrose bottles were changed every 6 hours. Consumption of regular drinking water and 1% sucrose solution over 24 hours was recorded and the animals' sugar water baseline was calculated. In the third stage, each mouse was raised in a single cage, and the mice were given equal amounts of plain drinking water and 1% sucrose solution, and the positions of the plain drinking water and sucrose bottles were changed every 6 hours. The consumption of regular drinking water and 1% sucrose solution over 24 hours was recorded and the sugar water preference of the animals was calculated.
The sugar water preference rate (%) is sugar water consumption/(sugar water consumption + consumption of ordinary drinking water) × 100%.
As a result: the sugar water preference of a mouse in a model group is remarkably reduced, and the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can remarkably improve the sugar water preference reduction condition of the mouse and relieve depression-like symptoms of the mouse, and the effect is consistent with that of a positive reference medicament fluoxetine.
Example 3 Tail suspension test
Tail suspension experiments for testing, mice were suspended on top of the equipment box above 50 cm from the ground. The experimental time was 6 minutes, the first 2 minutes was the adaptation time of the mice, and the last 4 minutes was the test time. The immobility time of the mice within 4 minutes after recording.
The motionless time is as follows: the mouse was in a suspended state and had no limb movement. The motionless time was measured using the ANY maze tracking system (Stoelting Co, Wood Dale, Illinois).
As a result: the immobility time of a model group mouse is obviously increased, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can obviously reduce the immobility time of the mouse and relieve depression-like symptoms of the mouse, and the effect is consistent with that of a positive reference medicament fluoxetine.
Example 4 forced swim test
The mice were placed in a glass cylinder (diameter: 20 cm; height: 25 cm) with a water depth of 15 cm and a water temperature of 23. + -. 1 ℃. The experimental time was 6 minutes, the first 2 minutes was the adaptation time of the mice, and the last 4 minutes was the test time. Cumulative immobility time of mice within 4 minutes after recording. Water change was required after each test.
The motionless time is as follows: when the mouse stops struggling, it floats in the water and remains immobile, or only makes some very slight movements necessary to keep the head afloat. The motionless time was measured using the ANY maze tracking system (Stoelting Co, Wood Dale, Illinois).
As a result: the immobility time of a model group mouse is obviously increased, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can obviously reduce the immobility time of the mouse and relieve depression-like symptoms of the mouse, and the effect is consistent with that of a positive reference medicament fluoxetine.
Example 516S diversity sequencing analysis
1) DNA extraction
And (3) separating and extracting total DNA of the sample by using a PowerMax DNA separation kit, and detecting the quantity and quality of the extracted DNA by using a spectrophotometer and agar gel electrophoresis respectively.
2)16S rDNA amplicon pyrosequencing
The V4 region fragment of the 16S rRNA gene extracted from a mouse stool specimen was subjected to PCR amplification using a forward primer 515F (5'-GTGCCAGCMGCCGCGGTAA-3') and a reverse primer 806R (5 '-GGACTACHVGGGTWTCTAAT-3'). PCR amplicons were purified with Agencour AMPure XP Beads and quantified with PicoGreen dsDNA assay kit. Amplicons were pooled in equal amounts and sequenced end-on at 2X 150bp using the Illlumina HiSeq4000 platform.
3) Sequence analysis
Sequencing data were processed using quantitative insights into microecology, in brief, primary sequencing reads that exactly match barcode were assigned to each sample and identified as valid sequences. Low quality sequences were filtered by the following criteria: sequences of length <150bp, sequences with an average Phred score <20, sequences containing ambiguous bases, sequences comprising a single nucleotide repetition rate >8 bp. Paired end readings were assembled using FLASH. Operational sorting unit (OTU) sorting was performed using Vsearch v1.11.1. OTU classification was performed by VSEARCH search for representative sequences set up against the SILVA128 database. An OTU table was further generated to record the abundance of each OTU in each sample and the classification of these OTUs. OTUs containing less than 0.001% of the total sequence in all samples were discarded. An averaged rounded sparse OTU table was generated by averaging 100 evenly resampled OTU subsets at 90% of the minimum sequencing depth for further analysis.
As a result: alpha analysis results show that the integral abundance and diversity of the intestinal flora of the mice in the model group are obviously reduced, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can obviously increase the integral abundance and diversity of the intestinal flora, and the effect is consistent with that of the positive reference medicament fluoxetine.
Further analysis shows that the relative abundance of the genera like Por _ Parabacteroides, Bac _ bacterioides and Ent _ Morganella of model groups is remarkably increased, the relative abundance of the genera like Cor _ Adlercreutzia, Lac _ Roseburia and Pas _ Agregabacter is remarkably reduced, and the relative abundance of the corresponding genera can be reduced or increased by the compound 1-diphenylmethyl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine; the effect is consistent with that of the positive reference drug fluoxetine.
The results suggest that the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine can improve the intestinal flora disorder of mice induced by a chronic unpredictable stress model.
Example 6 immunoblotting experiments
The improvement effect of the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine on the damage of the intestinal barrier and the blood brain barrier integrity of a mouse induced by a chronic unpredictable stress model is detected through an immunoblotting experiment. Preparing 15% SDS-PAGE electrophoresis gel, fully cracking hippocampal brain tissues of each group of mice, adding 1/4 volumes of 5 xSDS loading buffer solution, boiling for 5 minutes, loading according to 200 micrograms of total protein, transferring the protein onto a PVDF membrane by electrotransfer (350 milliamperes, 120 minutes), sealing for 1 hour at room temperature by using TBS/T containing 5% skimmed milk, reacting with ZO-1/Occludin/Claudin-5 antibody (1:500) at 4 ℃, washing the membrane for 3 times by daily TBS/0.5% Tween 20, incubating with an HRP-labeled secondary antibody chamber for 1 hour, washing the membrane for 3 times by using TBS/0.5% Tween 20, adding a premixed HRP chemiluminescence substrate, and detecting by using a chemiluminescence gel imaging system.
The compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine has an improvement effect on the integrity damage of mouse intestinal barriers induced by a chronic unpredictable stress model, the expression of ZO-1 and Occludin proteins in the intestinal tissues of mice in a model group is remarkably reduced, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can increase the expression of ZO-1 and Occludin proteins, the effect is consistent with that of a positive reference drug fluoxetine, and the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is suggested to be used for improving the integrity damage of mouse intestinal barriers induced by the chronic unpredictable stress model The injury can be improved.
The compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine has an improvement effect on blood brain barrier integrity damage of mice induced by a chronic unpredictable stress model. The expression of ZO-1, Occludin and Claudin-5 proteins in the brain tissues of mice in a model group is remarkably reduced, the expression of ZO-1, Occludin and Claudin-5 proteins can be increased by a compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine, the effect is consistent with that of a positive reference medicament fluoxetine, and the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine is prompted to have an improvement effect on blood brain barrier injury of mice induced by a chronic unpredictable stress model.
In some disclosures, the 1-benzhydryl-4-methylpiperazine compound is 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine.
In some disclosures, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine can be dissolved by normal saline to form a stable solution for use.
Principle of operation
The compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can improve the reduction of the integral abundance and diversity of mouse intestinal flora induced by a chronic unpredictable stress model, the reduction of the relative abundance of the genera such as Por _ Parabacteriides, Bac _ Bacteroides and Ent _ Morganella, and the increase of the relative abundance of the genera such as Cor _ Adlercutzia, Lac _ Roseburia and Pas _ Aggregator, thereby relieving the disturbance of the intestinal flora and further improving the depression symptom of the mouse;
meanwhile, the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazole-4-yl) methyl) piperazine can increase ZO-1 and Occludin protein expression in intestinal tract tissues to protect intestinal tract barrier integrity; increasing the expression of ZO-1, Occludin and Claudin-5 proteins in brain tissue protects the integrity of the blood brain barrier.
In the description herein, references to the description of "one embodiment," "an example," "a specific example," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the disclosure. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The foregoing illustrates and describes the general principles, principal features, and advantages of the present disclosure. It will be understood by those skilled in the art that the present disclosure is not limited to the embodiments described above, which are presented solely for purposes of illustrating the principles of the disclosure, and that various changes and modifications may be made to the disclosure without departing from the spirit and scope of the disclosure, which is intended to be covered by the claims.
Claims (5)
2. Use of the compound according to claim 1, wherein the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used for improving intestinal flora disorders: increase the overall richness and diversity of the intestinal flora.
3. Use of the compound according to claim 1, wherein the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used to decrease the relative abundance of Por _ parabacter, Bac _ bacteria and Ent _ Morganella in the intestine and to increase the relative abundance of Cor _ Adlercreutzia, Lac _ Roseburia and Pas _ agregegabacter.
4. Use of a compound according to claim 1, wherein the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used to protect gut barrier integrity and increase the expression of ZO-1 and Occludin proteins in intestinal tissue.
5. The use of a compound according to claim 1, wherein the compound 1-benzhydryl-4- ((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine is used to protect the integrity of the blood brain barrier and to increase the expression of ZO-1, occiudin and Claudin-5 proteins in brain tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110854248.4A CN113350348B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011225035.7A CN112245432B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of anti-depression drug |
CN202110854248.4A CN113350348B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011225035.7A Division CN112245432B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of anti-depression drug |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113350348A CN113350348A (en) | 2021-09-07 |
CN113350348B true CN113350348B (en) | 2022-03-01 |
Family
ID=74268208
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110854367.XA Active CN113398131B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparing medicine for improving intestinal flora disorder |
CN202110854248.4A Active CN113350348B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity |
CN202011225035.7A Active CN112245432B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of anti-depression drug |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110854367.XA Active CN113398131B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparing medicine for improving intestinal flora disorder |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011225035.7A Active CN112245432B (en) | 2020-11-05 | 2020-11-05 | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of anti-depression drug |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN113398131B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116359519B (en) * | 2023-05-29 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | CLDN5 protein, CLDN5 gene and application of modification thereof in diagnosis and/or treatment of depressive disorder |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3159635A (en) * | 1962-10-30 | 1964-12-01 | Searle & Co | 1-benzhydryl-4-(alkyl and aralkyl) aminopiperazines |
CZ20033092A3 (en) * | 2001-05-18 | 2004-08-18 | Astrazenecaáab | 4-(Phenyl piperazinyl methyl) benzamide derivatives and their use for treating pain, anxiety or gastrointestinal disorders |
CN106866555A (en) * | 2017-02-08 | 2017-06-20 | 东南大学 | The methyl piperazine class compound its preparation method of 1 benzhydryl 4 and application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101759683B (en) * | 2008-12-25 | 2011-12-28 | 哈尔滨誉衡药业股份有限公司 | Preparation method of hydrindene amide compound, medical composition comprising hydrindene amide compound and application thereof as protein kinase inhibitor |
SI2470166T1 (en) * | 2009-08-24 | 2014-03-31 | H.Lundbeck A/S | New compositions of 1-š2-(2,4-dimethyl-phenylsulfanyl)-phenylćpiperazine |
-
2020
- 2020-11-05 CN CN202110854367.XA patent/CN113398131B/en active Active
- 2020-11-05 CN CN202110854248.4A patent/CN113350348B/en active Active
- 2020-11-05 CN CN202011225035.7A patent/CN112245432B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3159635A (en) * | 1962-10-30 | 1964-12-01 | Searle & Co | 1-benzhydryl-4-(alkyl and aralkyl) aminopiperazines |
CZ20033092A3 (en) * | 2001-05-18 | 2004-08-18 | Astrazenecaáab | 4-(Phenyl piperazinyl methyl) benzamide derivatives and their use for treating pain, anxiety or gastrointestinal disorders |
CN106866555A (en) * | 2017-02-08 | 2017-06-20 | 东南大学 | The methyl piperazine class compound its preparation method of 1 benzhydryl 4 and application |
Also Published As
Publication number | Publication date |
---|---|
CN113398131B (en) | 2022-03-01 |
CN112245432A (en) | 2021-01-22 |
CN113350348A (en) | 2021-09-07 |
CN112245432B (en) | 2021-12-21 |
CN113398131A (en) | 2021-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiminez et al. | Butyrate supplementation at high concentrations alters enteric bacterial communities and reduces intestinal inflammation in mice infected with Citrobacter rodentium | |
Li et al. | Comparative study on gastrointestinal microbiota of eight fish species with different feeding habits | |
Enqi et al. | Comparison of the gut microbiota disturbance in rat models of irritable bowel syndrome induced by maternal separation and multiple early-life adversity | |
Zhang et al. | Environmental factors promote pathogen-induced skin ulceration syndrome outbreak by readjusting the hindgut microbiome of Apostichopus japonicus | |
Shao et al. | Changes to the gut microbiota in mice induced by infection with Toxoplasma gondii | |
Liu et al. | Tributyrin administration improves intestinal development and health in pre-weaned dairy calves fed milk replacer | |
CN113350348B (en) | Application of 1-benzhydryl-4-methylpiperazine compound in preparation of medicine for protecting intestinal barrier integrity | |
He et al. | Effect of early pathogenic escherichia coli infection on the intestinal barrier and immune function in newborn calves | |
Cao et al. | Susceptibility and immune responses of hybrid snakehead (Channa maculata♀× Channa argus♂) following infection with snakehead fish vesiculovirus | |
Hsu et al. | Revealing the compositions of the intestinal microbiota of three Anguillid eel species using 16S rDNA sequencing | |
Daly et al. | Host selectively contributes to shaping intestinal microbiota of carnivorous and omnivorous fish | |
Lingpeng et al. | Effect of water extracts from Cynanchum thesioides (Freyn) K. Schum. on visceral hypersensitivity and gut microbiota profile in maternally separated rats | |
Zhang et al. | Comparative analysis of midgut bacterial community under Vibrio splendidus infection in Apostichopus japonicus with hindgut as a reference | |
Goo et al. | Effects of Eimeria maxima infection doses on growth performance and gut health in dual-infection model of necrotic enteritis in broiler chickens | |
Meynier et al. | Pasteurized akkermansia muciniphila improves irritable bowel syndrome-like symptoms and related behavioral disorders in mice | |
Liu et al. | Comparative analysis of the fecal microbiota of relict gull (Larus relictus) in Mu Us Desert (Hao Tongcha Nur) and Bojiang Haizi in Inner Mongolia, China | |
von Scholten et al. | Aetiological factors behind adipose tissue inflammation: an unexplored research area | |
Guo et al. | Characterization of the pathogenesis and immune response to a highly virulent Edwardsiella tarda strain responsible for mass mortality in the hybrid snakehead (Channa maculate♀× Channa argus♂) | |
Zhang et al. | A longitudinal study reveals the alterations of the Microtus fortis colonic microbiota during the natural resistance to Schistosoma japonicum infection | |
CN109793760B (en) | Application of vibrio succinogenes in preparation of medicines for preventing or treating altitude diseases | |
Rosa et al. | Molecular markers for epithelial cells across gastrointestinal tissues and fecal RNA in preweaning dairy calves | |
Kim et al. | Abnormalities in red blood cell production and pathogenesis of anemia in the progression of rock bream iridovirus (RBIV) | |
US10441612B2 (en) | Intestinal microbe therapy, composition therefor and method for preparing the same | |
CN109718254A (en) | The bacillus gram that quivers, which belongs to, is preventing or is treating the application in the medicine of plateau | |
CN113750088B (en) | Application of heterocyclic compound in preparation of medicine for treating ulcerative colitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |